<?xml version="1.0" ?>
<text author="Rory  Cristiane Fortes De Brito, Jamille  Mirelle de Oliveira Cardoso, Levi  Eduardo Soares Reis, Fernando  Augusto Siqueira Mathias, Rodrigo  Dian de Oliveira Aguiar-Soares, Andréa Teixeira-Carvalho, Bruno  Mendes Roatt, Rodrigo Corrêa-Oliveira, Jeronimo  Conceição Ruiz, Daniela  de Melo Resende, Alexandre  Barbosa Reis" dateCollected="2019-11-03" id="autogum_academic_doc054" shortTile="synthetic-peptides" sourceURL="https://www.mdpi.com/2076-393X/7/4/162/htm" speakerCount="0" speakerList="none" title="Synthetic Peptides Elicit Strong Cellular Immunity in Visceral Leishmaniasis Natural Reservoir and Contribute to Long-Lasting Polyfunctional T-Cells in BALB/c Mice" type="academic">
<head>
<s type="frag">
4.	LS	@ord@
</s>
<s type="frag">
Discussion	NN	discussion
</s>
</head>
<p>
<s type="decl">
It	PRP	it
is	VBZ	be
believed	VBN	believe
that	IN	that
an	DT	an
ideal	JJ	ideal
vaccine	NN	vaccine
against	IN	against
<hi rend="italic">
Leishmania	NNP	Leishmania
spp	FW	spp
</hi>
.	.	.
</s>
<s type="decl">
should	MD	should
have	VB	have
epitopes	NNS	epitope
that	WDT	that
will	MD	will
be	VB	be
recognized	VBN	recognize
by	IN	by
APCs	NNPS	APCs
and	CC	and
will	MD	will
be	VB	be
able	JJ	able
to	TO	to
trigger	VB	trigger
a	DT	a
T-	JJ	T-
lymphocyte	NN	lymphocyte
effector	NN	effector
response	NN	response
and	CC	and
maintain	VB	maintain
a	DT	a
long-lasting	VBG	long-lasting
immune	NN	immune
memory	NN	memory
,	,	,
which	WDT	which
would	MD	would
be	VB	be
critical	JJ	critical
for	IN	for
protection	NN	protection
against	IN	against
the	DT	the
parasite	NN	parasite
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
the	DT	the
high-throughput	JJ	high-throughput
search	NN	search
for	IN	for
epitopes	NNS	epitope
with	IN	with
this	DT	this
potential	NN	potential
has	VBZ	have
become	VBN	become
one	CD	one
of	IN	of
the	DT	the
greatest	JJS	great
current	JJ	current
challenges	NNS	challenge
for	IN	for
the	DT	the
rational	JJ	rational
design	NN	design
of	IN	of
vaccines	NNS	vaccine
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
reverse	NN	reverse
vaccinology	NN	vaccinology
started	VBD	start
to	TO	to
be	VB	be
used	VBN	use
for	IN	for
this	DT	this
purpose	NN	purpose
,	,	,
and	CC	and
one	CD	one
of	IN	of
the	DT	the
strategies	NNS	strategy
used	VBN	use
is	VBZ	be
the	DT	the
search	NN	search
for	IN	for
immunogenic	JJ	immunogenic
epitopes	NNS	epitope
in	IN	in
whole	JJ	whole
<hi rend="italic">
Leishmania	NN	Leishmania
</hi>
proteomes	NNS	proteome
.	.	.
</s>
</p>
<p>
<s type="decl">
Epitope	NN	Epitope
mapping	NN	mapping
in	IN	in
proteomes	NNS	proteome
of	IN	of
parasites	NNS	parasites
is	VBZ	be
much	RB	much
more	RBR	more
complex	JJ	complex
than	IN	than
the	DT	the
mapping	NN	mapping
of	IN	of
epitopes	NNS	epitope
in	IN	in
proteins	NNS	protein
already	RB	already
described	VBN	describe
as	IN	as
immunogenic	JJ	immunogenic
.	.	.
</s>
<s type="decl">
In	IN	in
this	DT	this
way	NN	way
,	,	,
the	DT	the
use	NN	use
of	IN	of
the	DT	the
integrative	JJ	integrative
approach	NN	approach
to	TO	to
immunoinformatics	NNS	immunoinformatics
proposed	VBN	propose
by	IN	by
Brito	NNP	Brito
,	,	,
Guimaraes	NNP	Guimaraes
,	,	,
Velloso	NNP	Velloso
,	,	,
Correa-Oliveira	NNP	Correa-Oliveira
,	,	,
Ruiz	NNP	Ruiz
,	,	,
Reis	NNP	Reis
and	CC	and
Resende	NNP	Resende
was	VBD	be
important	JJ	important
to	TO	to
achieve	VB	achieve
potential	JJ	potential
epitopes	NNS	epitope
in	IN	in
this	DT	this
study	NN	study
.	.	.
</s>
<s type="decl">
After	IN	after
employing	VBG	employ
the	DT	the
immunoinformatics	NNS	immunoinformatics
methodologies	NNS	methodology
,	,	,
we	PRP	we
identified	VBD	identify
MHC	NNP	MHC
class	NN	class
I	PRP	I
and	CC	and
class	VBP	class
II	JJ	II
ligand	NN	ligand
epitopes	NNS	epitope
comprising	VBG	comprise
mouse	NN	mouse
and	CC	and
human	JJ	human
alleles	NNS	allele
,	,	,
due	JJ	due
to	TO	to
the	DT	the
absence	NN	absence
of	IN	of
predictors	NNS	predictor
comprising	VBG	comprise
dog	NN	dog
alleles	NNS	allele
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
based	VBN	base
on	IN	on
some	DT	some
studies	NNS	study
,	,	,
we	PRP	we
can	MD	can
verify	VB	verify
that	IN	that
there	EX	there
are	VBP	be
high	JJ	high
levels	NNS	level
of	IN	of
identity	NN	identity
between	IN	between
MHC	NNP	MHC
alleles	NNS	allele
of	IN	of
dogs	NNS	dog
and	CC	and
those	DT	those
of	IN	of
humans	NNS	human
and	CC	and
mice	NNS	mice
.	.	.
</s>
<s type="decl">
For	IN	for
example	NN	example
,	,	,
some	DT	some
loci	NNS	loci
of	IN	of
the	DT	the
MHC	NNP	MHC
region	NN	region
II	NNP	II
of	IN	of
dogs	NNS	dog
have	VBP	have
an	DT	an
identity	NN	identity
with	IN	with
those	DT	those
of	IN	of
humans	NNS	human
and	CC	and
mice	NNS	mice
around	RB	around
85	CD	@card@
%	NN	%
and	CC	and
79	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
.	.	.
</s>
</p>
<p>
<s type="decl">
Regarding	VBG	regard
the	DT	the
in	IN	in
vivo	FW	vivo
screening	NN	screen
of	IN	of
the	DT	the
immunoinformatics-selected	JJ	immunoinformatics-selected
peptides	NNS	peptide
in	IN	in
the	DT	the
canine	NN	canine
model	NN	model
,	,	,
we	PRP	we
selected	VBD	select
asymptomatic	JJ	asymptomatic
dogs	NNS	dog
naturally	RB	naturally
infected	VBN	infect
by	IN	by
<hi rend="italic">
L.	NNP	L.
infantum	FW	infantum
</hi>
(	-LRB-	(
natural	JJ	natural
reservoir	NN	reservoir
)	-RRB-	)
.	.	.
</s>
<s type="decl">
Several	JJ	several
studies	NNS	study
have	VBP	have
shown	VBN	show
that	IN	that
dogs	NNS	dog
and	CC	and
humans	NNS	human
with	IN	with
asymptomatic	JJ	asymptomatic
clinical	JJ	clinical
forms	NNS	form
have	VBP	have
better	JJR	good
reactivity	NN	reactivity
with	IN	with
intra-dermal	JJ	intra-dermal
reaction	NN	reaction
than	IN	than
symptomatic	JJ	symptomatic
individuals	NNS	individual
.	.	.
</s>
<s type="decl">
Similarly	RB	similarly
,	,	,
Reis	NNP	Reis
,	,	,
et	FW	et
al.	FW	al.
have	VBP	have
already	RB	already
shown	VBN	show
that	IN	that
asymptomatic	JJ	asymptomatic
dogs	NNS	dog
have	VBP	have
a	DT	a
profile	NN	profile
of	IN	of
circulating	VBG	circulate
lymphocytes	NNS	lymphocyte
in	IN	in
the	DT	the
peripheral	JJ	peripheral
blood	NN	blood
capable	RB	capable
of	IN	of
conferring	VBG	confer
a	DT	a
degree	NN	degree
of	IN	of
resistance	NN	resistance
to	TO	to
the	DT	the
disease	NN	disease
.	.	.
</s>
<s type="decl">
When	WRB	when
we	PRP	we
performed	VBD	perform
the	DT	the
in	IN	in
vitro	FW	vitro
screening	NN	screen
,	,	,
the	DT	the
purpose	NN	purpose
was	VBD	be
to	TO	to
identify	VB	identify
potential	JJ	potential
epitopes	NNS	epitope
in	IN	in
a	DT	a
huge	JJ	huge
number	NN	number
of	IN	of
peptides	NNS	peptide
.	.	.
</s>
<s type="decl">
For	IN	for
this	DT	this
,	,	,
we	PRP	we
focused	VBD	focus
on	IN	on
the	DT	the
main	JJ	main
biomarkers	NNS	biomarker
of	IN	of
protection	NN	protection
,	,	,
namely	RB	namely
:	:	:
lymphocyte	NN	lymphocyte
proliferation	NN	proliferation
after	IN	after
stimulation	NN	stimulation
with	IN	with
<hi rend="italic">
L.	FW	L.
infantum	FW	infantum
</hi>
and	CC	and
IFN-γ	NNP	IFN-γ
production	NN	production
by	IN	by
subpopulations	NNS	subpopulation
of	IN	of
T-lymphocytes	NNP	T-lymphocytes
(	-LRB-	(
CD4+	NNP	CD4+
and	CC	and
CD8+	NNP	CD8+
)	-RRB-	)
.	.	.
</s>
<s type="decl">
Currently	RB	currently
,	,	,
some	DT	some
markers	NNS	marker
related	VBN	relate
to	TO	to
protection	NN	protection
have	VBP	have
been	VBN	be
studied	VBN	study
,	,	,
such	JJ	such
as	IN	as
proinflammatory	JJ	proinflammatory
cytokines	NNS	cytokine
,	,	,
production	NN	production
of	IN	of
immunoglobulins	NNS	immunoglobulins
of	IN	of
IgG1	NNP	IgG1
and	CC	and
IgG2	NNP	IgG2
subtypes	NNS	subtype
,	,	,
and	CC	and
responsive	JJ	responsive
CD4+	NNS	CD4+
and	CC	and
CD8+	NN	CD8+
T-cells	NNS	T-cells
.	.	.
</s>
<s type="decl">
The	DT	the
biomarkers	NNS	biomarker
that	WDT	that
we	PRP	we
chose	VBD	choose
are	VBP	be
essential	JJ	essential
to	TO	to
determine	VB	determine
resistance	NN	resistance
or	CC	or
susceptibility	NN	susceptibility
to	TO	to
visceral	JJ	visceral
leishmaniasis	NN	leishmaniasis
and	CC	and
they	PRP	they
are	VBP	be
widely	RB	widely
demonstrated	VBN	demonstrate
in	IN	in
the	DT	the
literature	NN	literature
.	.	.
</s>
<s type="decl">
Our	PRP$	our
data	NNS	datum
support	VBP	support
that	IN	that
some	DT	some
peptides	NNS	peptide
were	VBD	be
able	JJ	able
to	TO	to
induce	VB	induce
lymphoproliferation	NN	lymphoproliferation
and	CC	and
the	DT	the
production	NN	production
of	IN	of
IFN-γ	NNP	IFN-γ
by	IN	by
T-cells	NNPS	T-cells
in	IN	in
vitro	FW	vitro
.	.	.
</s>
<s type="decl">
In	IN	in
this	DT	this
regard	NN	regard
,	,	,
in	IN	in
many	JJ	many
studies	NNS	study
reporting	VBG	report
the	DT	the
use	NN	use
of	IN	of
murine	NN	murine
model	NN	model
and	CC	and
PBMC	NN	PBMC
from	IN	from
patients	NNS	patient
with	IN	with
leishmaniasis	NN	leishmaniasis
,	,	,
the	DT	the
main	JJ	main
biomarker	NN	biomarker
analyzed	VBD	analyze
was	VBD	be
IFN-γ	NNP	IFN-γ
produced	VBN	produce
after	IN	after
stimuli	NNS	stimulus
with	IN	with
different	JJ	different
peptides	NNS	peptide
.	.	.
</s>
</p>
<p>
<s type="decl">
After	IN	after
the	DT	the
in	IN	in
vitro	FW	vitro
screening	NN	screen
,	,	,
the	DT	the
reverse	JJ	reverse
antigen	NN	antigen
screening	NN	screen
(	-LRB-	(
RAS	NNP	RAS
)	-RRB-	)
was	VBD	be
used	VBN	use
,	,	,
a	DT	a
robust	JJ	robust
methodology	NN	methodology
that	WDT	that
allows	VBZ	allow
the	DT	the
selection	NN	selection
of	IN	of
promising	VBG	promising
targets	NNS	target
for	IN	for
the	DT	the
development	NN	development
of	IN	of
vaccines	NNS	vaccine
intended	VBN	intend
to	TO	to
trigger	VB	trigger
a	DT	a
strong	JJ	strong
cellular	JJ	cellular
response	NN	response
.	.	.
</s>
<s type="decl">
Our	PRP$	our
findings	NNS	finding
demonstrate	VBP	demonstrate
that	IN	that
an	DT	an
immunoinformatic	JJ	immunoinformatic
approach	NN	approach
increases	VBZ	increase
the	DT	the
chance	NN	chance
of	IN	of
finding	VBG	finding
peptides	NNS	peptide
molecules	NNS	molecule
(	-LRB-	(
epitopes	NNS	epitope
)	-RRB-	)
which	WDT	which
can	MD	can
trigger	VB	trigger
a	DT	a
cellular	JJ	cellular
response	NN	response
in	IN	in
a	DT	a
naturally	RB	naturally
and	CC	and
asymptomatic	JJ	asymptomatic
infected	VBN	infect
model	NN	model
.	.	.
</s>
<s type="decl">
The	DT	the
fact	NN	fact
that	IN	that
an	DT	an
antigen	NN	antigen
generates	VBZ	generate
a	DT	a
cellular	JJ	cellular
response	NN	response
classified	VBN	classify
as	IN	as
type	NN	type
IV	NN	IV
or	CC	or
late	JJ	late
hypersensitivity	NN	hypersensitivity
implies	VBZ	imply
that	IN	that
this	DT	this
antigen	NN	antigen
may	MD	may
be	VB	be
able	JJ	able
to	TO	to
generate	VB	generate
immune	JJ	immune
memory	NN	memory
and	CC	and
trigger	VB	trigger
a	DT	a
response	NN	response
characterized	VBN	characterize
by	IN	by
important	JJ	important
cytokines	NNS	cytokine
,	,	,
such	JJ	such
as	IN	as
IFN-γ	NNP	IFN-γ
and	CC	and
TNF-α	NNP	TNF-α
.	.	.
</s>
<s type="decl">
When	WRB	when
we	PRP	we
analyzed	VBD	analyze
the	DT	the
epitope	NN	epitope
conservancy	NN	conservancy
of	IN	of
these	DT	these
peptides	NNS	peptide
among	IN	among
the	DT	the
proteome	NN	proteome
of	IN	of
other	JJ	other
<hi rend="italic">
Leishmania	NNP	Leishmania
</hi>
species	NNS	specie
,	,	,
it	PRP	it
was	VBD	be
observed	VBN	observe
that	IN	that
peptide	NN	peptide
PEP17	NNP	PEP17
demonstrated	VBD	demonstrate
to	TO	to
be	VB	be
the	DT	the
most	RBS	most
conserved	VBN	conserve
epitope	NN	epitope
among	IN	among
various	JJ	various
viscerotropic	NN	viscerotropic
and	CC	and
dermatotropic	JJ	dermatotropic
<hi rend="italic">
Leishmania	FW	Leishmania
</hi>
species	NNS	specie
.	.	.
</s>
<s type="sub">
Immunogenic	JJ	Immunogenic
peptides	NNS	peptide
that	WDT	that
show	VBP	show
a	DT	a
high	JJ	high
degree	NN	degree
of	IN	of
conservancy	NN	conservancy
with	IN	with
other	JJ	other
parasites	NNS	parasites
may	MD	may
be	VB	be
related	VBN	relate
to	TO	to
a	DT	a
better	JJR	good
protection	NN	protection
when	WRB	when
compared	VBN	compare
to	TO	to
those	DT	those
not	RB	not
conserved	VBN	conserve
.	.	.
</s>
<s type="decl">
In	IN	in
this	DT	this
way	NN	way
,	,	,
peptides	NNS	peptide
17	CD	@card@
,	,	,
30	CD	@card@
,	,	,
33	CD	@card@
,	,	,
and	CC	and
34	CD	@card@
may	MD	may
be	VB	be
considered	VBN	consider
promising	VBG	promising
epitopes	NNS	epitope
for	IN	for
the	DT	the
design	NN	design
of	IN	of
vaccines	NNS	vaccine
against	IN	against
VL	NN	VL
.	.	.
</s>
</p>
</text>
